Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes

被引：0
|
作者：
DeFronzo, R
Ratner, R
Han, J
Kim, D
Fineman, M
Baron, A
机构：
[1] Univ Texas, Hlth Sci Ctr, Diabet Div, San Antonio, TX USA
[2] George Washington Univ, Sch Med, Dept Med, Bethesda, MD USA
[3] Amylin Pharmaceut Inc, Clin Affairs, San Diego, CA USA
来源：
DIABETOLOGIA | 2004年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
775
引用
收藏
页码：A280 / A280
页数：1
相关论文
共 50 条
  • [31] Simultaneous reduction in both HbA1c and body weight with canagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes mellitus over 104 weeks
    Langslet, G.
    Leiter, L. A.
    Vijapurkar, U.
    Davies, M.
    Canovatchel, W.
    DIABETOLOGIA, 2015, 58 : S353 - S354
  • [32] Timing of Exercise Affects Glycemic Control in Type 2 Diabetes Patients Treated with Metformin
    Huang, Tao
    Lu, Chunyan
    Schumann, Moritz
    Le, Shenglong
    Yang, Yifan
    Zhuang, Haihui
    Lu, Qingwei
    Liu, Jinsheng
    Wiklund, Petri
    Cheng, Sulin
    JOURNAL OF DIABETES RESEARCH, 2018, 2018
  • [33] Exenatide monotherapy improves glycemic control and is well tolerated over 24 weeks in drug-naive patients with type 2 diabetes
    Brodows, Robert
    Milton, Denai
    Ridge, Terry D.
    Macconell, Leigh
    Okerson, Ted
    Wolka, Anne M.
    Moretto, Thomas J.
    DIABETES, 2008, 57 : A145 - A145
  • [34] Predictors of glycemic and weight responses to exenatide in patients with type 2 diabetes mellitus
    Yuhan Huang
    Yanan Yu
    Ruonan Hu
    Ke Xu
    Tao Wang
    Hongwei Ling
    Jia Han
    Dongmei Lv
    International Journal of Diabetes in Developing Countries, 2024, 44 : 328 - 334
  • [35] Predictors of glycemic and weight responses to exenatide in patients with type 2 diabetes mellitus
    Huang, Yuhan
    Yu, Yanan
    Hu, Ruonan
    Xu, Ke
    Wang, Tao
    Ling, Hongwei
    Han, Jia
    Lv, Dongmei
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2024, 44 (02) : 328 - 334
  • [36] One Year Exenatide Therapy, Compared with Insulin Glargine, Reduces Postprandial Oxidative Stress in Metformin-Treated Patients with Type 2 Diabetes
    Bunck, Mathijs C.
    Corner, Anja
    Eliasson, Bjorn
    Wu, Yan
    Shaginian, Rimma M.
    Yan, Ping
    Heine, Robert J.
    Smith, Ulf
    Yki-Jaervinen, Hannele
    Taskinen, Marja-Riitta
    Diamant, Michaela
    DIABETES, 2009, 58 : A147 - A147
  • [37] Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
    Kolterman, OG
    Buse, JB
    Fineman, MS
    Gaines, E
    Heintz, S
    Bicsak, TA
    Taylor, K
    Kim, D
    Aisporna, M
    Wang, Y
    Baron, AD
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (07): : 3082 - 3089
  • [38] Improved patient satisfaction with ITCA 650 vs. exenatide injections in subjects with metformin-treated type 2 diabetes
    Alessi, T.
    Henry, R. R.
    Rosenstock, J.
    Luskey, K.
    DIABETOLOGIA, 2011, 54 : S319 - S319
  • [39] Safety and efficacy of exenatide over 16 weeks in patients with type 2 diabetes mellitus using a thiazolidinedione with or without metformin
    Zinman, B.
    Hoogwerf, B.
    Garcia, S. Duran
    Milton, D.
    Giaconia, J.
    Kim, D.
    Trautmann, M.
    Brodows, R.
    DIABETOLOGIA, 2006, 49 : 475 - 476
  • [40] Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    Bosi, Emanuele
    Camisasca, Riccardo Paolo
    Collober, Carole
    Rochotte, Erika
    Garber, Alan J.
    DIABETES CARE, 2007, 30 (04) : 890 - 895
12345